A Phase 3 interventional study of Amlodipine 10 mg and Aliskiren 150 in Hypertension, sponsored by Novartis. Completed at 7 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-27.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 30th largest by enrollment of the 186 interventional ones that give a count, is one of 14 that started in 2008, is one of 69 in phase 3, and was the 67th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 847 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 40th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 148th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of combination aliskiren/amlodipine in patients with hypertension not adequately controlled with amlodipine alone.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Amlodipine 10 mg
Drug: Amlodipine 10 mg
Aliskiren/Amlodipine 150/10 mg
Drug: Amlodipine 10 mg · Drug: Aliskiren 150
Aliskiren/Amlodipine 300/10 mg
Drug: Amlodipine 10 mg · Drug: Amlodipine 300
Amlodipine 10 mg
Aliskiren/Amlodipine 150/10 mg
Aliskiren/Amlodipine 300/10 mg
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study
Time frame: Baseline and Week 8
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study
Time frame: Baseline and Week 8
Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group
Time frame: 8 weeks
Biomarker Assessment at Visit 2 (Single Blind Run in), Visit 5 (Randomization), and Visit 9 (EOS)
Time frame: 12 weeks
| Milestone | Aliskiren/Amlodipine 300/10 mg | Aliskiren/Amlodipine 150/10 mg | Amlodipine 10 mg |
|---|---|---|---|
| Started | 279 | 285 | 283 |
| Completed | 261 | 266 | 255 |
| Not completed | 18 | 19 | 28 |
| Withdrew: Adverse event | 9 | 10 | 14 |
| Withdrew: Abnormal laboratory value(s) | 1 | 0 | 0 |
| Withdrew: Abnormal test procedure result(s) | 0 | 0 | 2 |
| Withdrew: Unsatisfactory therapeutic response | 1 | 1 | 1 |
| Withdrew: Patient no longer requires study drug | 0 | 1 | 0 |
| Withdrew: Patient withdrew request | 3 | 1 | 6 |
| Withdrew: Lost to follow-up | 0 | 2 | 1 |
| Withdrew: Administrative problems | 1 | 2 | 0 |
| Withdrew: Protocol violation | 3 | 0 | 2 |
| Withdrew: Not treated | 0 | 2 | 2 |
| mm Hg | Aliskiren/Amlodipine 300/10 mg | Aliskiren/Amlodipine 150/10 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study | -10.99 ± 0.462 | -8.95 ± 0.460 | -7.23 ± 0.459 |
| mm Hg | Aliskiren/Amlodipine 300/10 mg | Aliskiren/Amlodipine 150/10 mg | Amlodipine 10 mg |
|---|---|---|---|
| Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study | -14.42 ± 0.684 | -11.01 ± 0.681 | -8.20 ± 0.680 |
| Participants | Aliskiren/Amlodipine 300/10 mg | Aliskiren/Amlodipine 150/10 mg | Amlodipine 10 mg |
|---|---|---|---|
| Number of Patients With Any Adverse Event and/or Serious Adverse Event in the Double-blind Period by Treatment Group | 87 | 99 | 92 |
Results for this outcome have not been posted.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren 300mg/ Amlodipine 10mg | — | 4/279 (1.4%) | 31/279 (11.1%) |
| Aliskiren 150mg/ Amlodipine 10mg | — | 1/283 (0.4%) | 35/283 (12.4%) |
| Amlodipine 10mg | — | 0/281 (0%) | 40/281 (14.2%) |
| Event | Aliskiren 300mg/ Amlodipine 10mg | Aliskiren 150mg/ Amlodipine 10mg | Amlodipine 10mg |
|---|---|---|---|
| Lymphoid tissue hyperplasiaBlood and lymphatic system disorders | 1/279 | 0/283 | 0/281 |
| Tendon ruptureInjury, poisoning and procedural complications | 1/279 | 0/283 | 0/281 |
| Renal artery stenosisRenal and urinary disorders | 1/279 | 0/283 | 0/281 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 1/279 | 0/283 | 0/281 |
| Joint injuryInjury, poisoning and procedural complications | 0/279 | 1/283 | 0/281 |
| Event | Aliskiren 300mg/ Amlodipine 10mg | Aliskiren 150mg/ Amlodipine 10mg | Amlodipine 10mg |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 15/279 | 23/283 | 25/281 |
| NasopharyngitisInfections and infestations | 16/279 | 15/283 | 15/281 |
| Age, Continuous(years) | Aliskiren/Amlodipine 300/10 mg | Aliskiren/Amlodipine 150/10 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| Mean | 55.2 ± 10.19 | 54.4 ± 10.70 | 54.3 ± 10.92 | 54.6 ± 10.60 |
| Sex: Female, Male(Participants) | Aliskiren/Amlodipine 300/10 mg | Aliskiren/Amlodipine 150/10 mg | Amlodipine 10 mg | Total |
|---|---|---|---|---|
| Female | 116 | 113 | 99 | 328 |
| Male | 163 | 172 | 184 | 519 |
The record gives a start of Oct 2008, a primary completion of Jun 2009 and a completion of Jun 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlodipine